Bluejay Diagnostics (BJDX) Cash & Equivalents (2020 - 2026)

Bluejay Diagnostics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 18.24% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (up 18.24% YoY), while the FY2025 annual figure was $5.2 million, up 20.06% from the prior year.
• Cash & Equivalents came in at $3.7 million for Q1 2026 at Bluejay Diagnostics, down from $5.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $17.1 million in Q1 2022 to a low of $2.2 million in Q4 2023.
• A 5-year average of $6.8 million and a median of $5.1 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 470.33% in 2022 and sank 78.17% in 2023, its largest moves.
• Bluejay Diagnostics' Cash & Equivalents stood at $10.1 million in 2022, then tumbled by 78.17% to $2.2 million in 2023, then jumped by 94.79% to $4.3 million in 2024, then advanced by 20.06% to $5.2 million in 2025, then slipped by 28.66% to $3.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.7 million, $5.2 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison